<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500186</url>
  </required_header>
  <id_info>
    <org_study_id>Kanden-hsp-0001</org_study_id>
    <secondary_id>UMIN000017838</secondary_id>
    <nct_id>NCT02500186</nct_id>
  </id_info>
  <brief_title>The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor</brief_title>
  <official_title>The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansai Electric Power Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Corporation Heishinkai OCROM Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kansai Electric Power Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this clinical study is to assess the effect of the amount of carbohydrate&#xD;
      intake and meals differing in glycemic index (GI) in patients of type 2 diabetes mellitus&#xD;
      treated with an SGLT2 inhibitor (Luseogliflozin), which inhibits glucose reabsorption from&#xD;
      renal uriniferous tubule, on glucose variability by using continuous glucose monitoring&#xD;
      (CGM), and to establish dietary therapy which reduces the risk of hypoglycemia in patients&#xD;
      treated with SGLT2 inhibitors. In addition, blood and urine samples are collected for&#xD;
      metabolome analysis that will be performed as an extension study of the clinical study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &lt;Background and Rationale&gt; In order to decrease the risk of hypoglycemia caused by SGLT2&#xD;
      inhibitor, it is necessary to review the effect of the volume of carbohydrate intake and the&#xD;
      level of GI value on variation of blood glucose.&#xD;
&#xD;
      Also, if a patient with chronic lack of carbohydrate intake receives SGLT2 inhibitors, there&#xD;
      is a risk of serious hypoglycemic reaction. Thus, the establishment of proper meal for&#xD;
      patients receiving SGLT2 inhibitors is the urgent task.&#xD;
&#xD;
      The objective of this study is to establish a safe dietary therapy for patients with type 2&#xD;
      diabetes mellitus to avoid hypoglycemia by controlling carbohydrate intake volume and GI&#xD;
      value, where study patients are provided study meal three times a day and circadian blood&#xD;
      glucose variation including blood glucose after meal is measured by using CGM.&#xD;
&#xD;
      In addition, blood and urine samples are collected for the future research (metabolome&#xD;
      analysis) on the effect of carbohydrate intake volume and GI value on metabolism to be&#xD;
      conducted as an extended study of this study.&#xD;
&#xD;
      &lt;Study Procedures&gt; Total of 24 study patients with type 2 diabetes mellitus who have not&#xD;
      taken or washed out hypoglycemic drug (oral hypoglycemic drug and glucagon like peptide-1&#xD;
      receptor agonist) for at least 4 weeks are randomized into 3 groups (8 patients each) of high&#xD;
      GI meal containing 55% carbohydrate group, low GI meal containing 55% carbohydrate group, and&#xD;
      high GI meal containing 40% carbohydrate group. The energy intake of study patients in all&#xD;
      the groups is 1800 kcal per day. Each study group patient takes the following diets for 14&#xD;
      days; study patients in high GI meal containing 55% carbohydrate group take 55% carbohydrate&#xD;
      white rice diet; those in low GI meal containing 55% carbohydrate group take 55% carbohydrate&#xD;
      brown rice diet; those in high GI meal containing 40% carbohydrate group take 40%&#xD;
      carbohydrate white rice diet. Study patients orally receive luseogliflozin 2.5 mg s.i.d.&#xD;
      before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.&#xD;
&#xD;
      Planned examinations are conducted at the initiation of the study meal, the initiation of the&#xD;
      study treatment, and the completion of the clinical study. Blood glucose is measured on 4&#xD;
      days from the 3rd day of the initiation of the study meal to pre-dose of study treatment and&#xD;
      from 2 days before study treatment completion to the next day of study treatment so that&#xD;
      blood glucose data of continuous 48 hours at one time can be obtained.&#xD;
&#xD;
      &lt;Time and process of getting informed consents&gt; Principal investigator or sub-investigator&#xD;
      fully explains the clinical study to candidate patients using informed consent form approved&#xD;
      by the Institutional Review Board prior to the study procedure and obtains written informed&#xD;
      consent from subjects on voluntary basis after confirming that patients duly understand the&#xD;
      content of the clinical study. Principal investigator or sub-investigator who gives&#xD;
      explanation to patients and study patients affix a name and seal or give a signature and&#xD;
      enter the date on the informed consent form. If study collaborator gives supplementary&#xD;
      explanation, the collaborator also affixes a name and seal or give a signature and enter the&#xD;
      date.&#xD;
&#xD;
      Principal investigator or sub-investigator provided the copy of the informed consent form to&#xD;
      study patients who gave informed consent to participate in the clinical study and record&#xD;
      them.&#xD;
&#xD;
      Principal investigator or sub-investigator documents the date of informed consent on case&#xD;
      report form.&#xD;
&#xD;
      &lt;Screening Examination&gt; The eligibility for the clinical study of candidate patients who gave&#xD;
      written informed consent are judged through the following examinations.&#xD;
&#xD;
      Candidate patients undergo screening examinations between 28 days and one day before the&#xD;
      initiation of test meal (if the patient takes one hypoglycemic drug, between 28 days and one&#xD;
      day before the initiation of washout).&#xD;
&#xD;
      Demographic background: date of birth, race, sex, disease duration of type 2 diabetes&#xD;
      mellitus, drug and therapy used for treatment of type 2 diabetes mellitus within 3 months&#xD;
      prior to the study procedure, complications / medical history, concomitant drug / therapy,&#xD;
      drinking / smoking status, height / weight / BMI Examination item: physical examination,&#xD;
      measurement of body fluid volume (by impedance method), clinical laboratory tests, vital&#xD;
      signs (blood pressure, pulse rate, body temperature) &lt;Statistical Analysis&gt;&#xD;
&#xD;
        1. Demographic and Other Baseline Characteristics Efficacy analysis set and Safety analysis&#xD;
           set are used for the analysis. For discrete values, frequency is summarized by group;&#xD;
           for continuous data, summary statistics is calculated. Comparison between groups is also&#xD;
           conducted.&#xD;
&#xD;
        2. Analysis of primary endpoint (Efficacy endpoint) Efficacy analysis set is used for the&#xD;
           analysis. Summary statistics of blood glucose level by using CGM is calculated.&#xD;
           Comparison between groups is also conducted.&#xD;
&#xD;
        3. Analysis of Secondary endpoint (Safety endpoint or efficacy endpoint) Safety analysis&#xD;
           set and Efficacy analysis set are used for the analysis and the followings are&#xD;
           summarized and analyzed.&#xD;
&#xD;
           For discrete values of clinical laboratory tests and vital signs, frequency is&#xD;
           summarized by group; for continuous data, summary statistics is calculated by group.&#xD;
&#xD;
           Summary statistics of adverse event is calculated by group.&#xD;
&#xD;
        4. Significance level of test and confidence coefficient of confidence interval Tests are&#xD;
           two-sided with the significance level of 5%. Confidence intervals are estimated with&#xD;
           coefficient of 95%. &lt;Sample size&gt; Determination of sample size 24 patients (8 for each&#xD;
           group) The sample size is 8 patients for each group because the size is operable and&#xD;
           appropriate for analysis for the study.&#xD;
&#xD;
      &lt;Action to be taken to study patients when an adverse event occurs&gt; If an adverse event is&#xD;
      observed, principal investigator or sub-investigator provides treatment or follow-up to the&#xD;
      study patients until the patient recovers from the adverse event or the follow-up is judged&#xD;
      to be unneccesary by medically explainable reason. If follow-up examination, additional&#xD;
      examination, or re-examination is necessary, they are conducted after obtaining the study&#xD;
      patient's informed consent.&#xD;
&#xD;
      Principal investigator or sub-investigator documents the name of adverse event, date of&#xD;
      occurrence, intensity, seriousness, study drug adjustment, treatment for the adverse event,&#xD;
      outcome, date of outcome, and relationship with the clinical study. For an adverse event&#xD;
      which is observed from the initiation of the study drug administration to follow-up&#xD;
      examination, the relationship with the study drug is also documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood glucose level using CGM</measure>
    <time_frame>From Day 6 to Day 7, and from Day 13 and Day 14</time_frame>
    <description>Early morning on 8th and 15th day after the initiation of test meal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Hematologic test (White blood cell) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hematologic test (Ratio of neutrophils) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hematologic test (Ratio of lymphocyte) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hematologic test (Ratio of monocyte) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hematologic test (Ratio of eosinophils) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hematologic test (Ratio of basophils) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hematologic test (Hemoglobin) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hematologic test (Hematocrit) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hematologic test (Blood platelet) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Total cholesterol) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (High-density lipoprotein cholesterol) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Low-density lipoprotein cholesterol) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Triglyceride) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Albumin) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Total bilirubin) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Aspartate aminotransferase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Alanine aminotransferase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Lactase dehydrogenase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Alkaline phosphatase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Î³-glutamyltransferase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Creatine kinase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Amylase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Lipase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Blood urea nitrogen) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Urinary acid) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Lactic acid) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Ketone body) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Creatinine) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Natrium) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Kalium) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Chlorine) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Calcium) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Glucose) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Hemoglobin A1c) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Plasma fatty acid composition) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Non-esterified fatty acid) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Insulin) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (C-peptide) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Glucagon) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Choline esterase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Cross-linked N-telopeptide of type 1 collagen) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Biochemical examination of blood (Bone alkaline phosphatase) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary Qualitative (Sugar) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary Qualitative (Protein) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary Qualitative (Ketone body) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary Qualitative (Uric blood) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary sediment (Red blood cell) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary sediment (White blood cell) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary sediment (Squamous cell) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary sediment (Transitional cell) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary sediment (Urine creatinine) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary sediment (Urinary albumin) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Urinary sediment (Urinary cytology) from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Body temperature rate from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Blood pressure rate from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Pulse rate from baseline (Day 1) to Day 15</measure>
    <time_frame>On Day 1 (before the start of test meal), Day 8 (pre-dose), and Day 15 (post-dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From screening examination to Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Melltius, Type 2</condition>
  <arm_group>
    <arm_group_label>High GI meal containing 55% carbohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 55% carbohydrate group take 55% carbohydrate white rice diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low GI meal containing 55% carbohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The energy intake of study patients is 1800 kcal per day. Study patients in low GI meal containing 55% carbohydrate group take 55% carbohydrate brown rice diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High GI meal containing 40% carbohydrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 40% carbohydrate group take 40% carbohydrate white rice diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luseogliflozin</intervention_name>
    <description>Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.</description>
    <arm_group_label>High GI meal containing 40% carbohydrate</arm_group_label>
    <arm_group_label>High GI meal containing 55% carbohydrate</arm_group_label>
    <arm_group_label>Low GI meal containing 55% carbohydrate</arm_group_label>
    <other_name>Lusefi tab. 2.5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Meal containing different carbohydrate ratio and GI value</intervention_name>
    <description>High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate</description>
    <arm_group_label>High GI meal containing 40% carbohydrate</arm_group_label>
    <arm_group_label>High GI meal containing 55% carbohydrate</arm_group_label>
    <arm_group_label>Low GI meal containing 55% carbohydrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Japanese patients with type 2 diabetes&#xD;
&#xD;
          2. Patients aged 20 to 64, inclusive, when obtaining written informed consent, regardless&#xD;
             of sex&#xD;
&#xD;
          3. Patients with HbA1c (NGSP) between 7.0 and 10.0 % at screening examination or patients&#xD;
             with HbA1c (NGSP) &lt;= 10.0 % (no lower limit) at screening examination if they receive&#xD;
             one kind of hypoglycemic drug (oral hypoglycemic drug or GLP-1 receptor agonist)&#xD;
&#xD;
          4. Patients with BMI &gt;= 20 kg/m2 and &lt; 30 kg/m2&#xD;
&#xD;
          5. Outpatients&#xD;
&#xD;
          6. Patients who was explained about the clinical study, understood the content of the&#xD;
             study, and gave written informed consent before participating in the clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are diagnosed as diabetes mellitus other than type 2 diabetes, e.g., type&#xD;
             1 diabetes, diabetes with specific mechanism or disease except for type 2 diabetes,&#xD;
             pregnancy diabetes&#xD;
&#xD;
          2. Patients with complication of severe kidney dysfunction, e.g., nephrotic syndrome,&#xD;
             renal failure, dialytic therapy&#xD;
&#xD;
          3. Patients with eGFR &lt; 45mL/min/1.73m2 at screening examination&#xD;
&#xD;
          4. Patients with complication of severe hepatic disorder, e.g., hepatocirrhosis&#xD;
&#xD;
          5. Patients with complication of severe heart disease, e.g., cardiac infarction, cardiac&#xD;
             failure, or of cerebral infarction, or patients with medical history of those within 6&#xD;
             months prior to the initiation of the clinical study (obtaining informed consent)&#xD;
&#xD;
          6. Patients who have serious complication of gastrointestinal disorders or who underwent&#xD;
             a surgical operation that is known to affect the absorption of a drug by digestive&#xD;
             tract&#xD;
&#xD;
          7. Patients with diabetic microangiopathy, e.g., retinopathy of diabetes, diabetic&#xD;
             neuropathy, or others which cannot be fully controlled regardless of continuing&#xD;
             treatment&#xD;
&#xD;
          8. Patients who are susceptible to dehydration (Patients with extremely poorly-controlled&#xD;
             glycemia)&#xD;
&#xD;
          9. Patients with complication of malignancy (Patients who recovered from malignancy are&#xD;
             permitted to participate in the clinical study)&#xD;
&#xD;
         10. Patients with a history of hypersensitivity to Luseogliflozin&#xD;
&#xD;
         11. Patients who is a chronic heavy drinker&#xD;
&#xD;
         12. Female patients who are pregnant, possibly pregnant, or breast-feeding&#xD;
&#xD;
         13. Other patients who are judged as ineligible for enrollment in the clinical study by&#xD;
             the principal investigator or subinvestigat or subinvestigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yutaka Seino, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Kansai Electric Power Hospital</affiliation>
  </overall_official>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>June 8, 2018</last_update_submitted>
  <last_update_submitted_qc>June 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

